(Q54218013)

26 May 2018

title

Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer. (English)

1 reference

26 May 2018

1 reference

3

H Madjar

0 references

author name string

A du Bois

1

1 reference

26 May 2018

H G Meerpohl

2

1 reference

26 May 2018

D Spinner

4

1 reference

26 May 2018

P Dall

5

1 reference

26 May 2018

J Pfisterer

6

1 reference

26 May 2018

T Bauknecht

7

1 reference

26 May 2018

publication date

1 January 1994

1 reference

26 May 2018

Journal of Cancer Research and Clinical Oncology

published in

1 reference

26 May 2018

volume

120

1 reference

26 May 2018

issue

3

1 reference

26 May 2018

page(s)

173-178

1 reference

26 May 2018

https://scigraph.springernature.com/pub.10.1007/bf01202198

exact match

0 references

cites work

Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity

1 reference

12 December 2020

A randomized controlled study of (2"R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in

1 reference

12 December 2020

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer

1 reference

12 December 2020

A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics

1 reference

12 December 2020

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

1 reference

12 December 2020

High-dose carboplatin in refractory ovarian cancer patients.

1 reference

12 December 2020

Response to second line chemotherapy in ovarian cancer of epithelial origin

1 reference

12 December 2020

Epirubicin for pretreated advanced ovarian cancer

1 reference

12 December 2020

Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines.

1 reference

12 December 2020

Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin

1 reference

12 December 2020

Early assessment of a new anticancer drug analogue--are the historical comparisons obsolete? The French experience with pirarubicin

1 reference

12 December 2020

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

12 December 2020

Use of high dose cis-dichlorodiammine platinum (II) (NSC--119875) following failure on previous chemotherapy for advanced carcinoma of the ovary

1 reference

12 December 2020

Phase II study of (2''R)-4'-O-tetrahydropyranyladriamycin (THP) in patients with solid tumors. Multi-Institutional Cooperative Study

1 reference

12 December 2020

Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer

1 reference

12 December 2020

Pirarubicin in advanced breast cancer: a French cooperative phase II study

1 reference

12 December 2020

Pirarubicin (4'-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A Clinical Phase II study

1 reference

12 December 2020

Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron

1 reference

12 December 2020

Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma

1 reference

12 December 2020

High-dose platinum for the treatment of refractory ovarian cancer

1 reference

12 December 2020

Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro

1 reference

12 December 2020

Phase II study with pirarubicin in pretreated progressive head-neck neoplasms

1 reference

12 December 2020

Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy

1 reference

12 December 2020

Treatment of advanced ovarian cancer: 10 years of experience

1 reference

12 December 2020

Phase II study of pirarubicin in advanced non-small cell lung cancer

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Phase II study of pirarubicin in metastatic breast cancer

1 reference

12 December 2020

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

12 December 2020

Activity of pirarubicin (4'-0-tetrahydropyranyladriamycin) in malignant mesothelioma

1 reference

12 December 2020

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

12 December 2020

Activity of 4'-0-tetrahydropyranyladriamycin hydrochloride (THP-ADM) in a human tumor cloning system

1 reference

12 December 2020

Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study

1 reference

12 December 2020

Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration

1 reference

12 December 2020

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

1 reference

12 December 2020

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01202198

1 reference

26 May 2018

PubMed ID

8263015

1 reference

26 May 2018